A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

The following contains links to social media websites including Bluesky, X, TikTok, Instagram, Facebook, and LinkedIn. "Make ...

As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

Feb. 12, 2024 – People with type 2 diabetes taking GLP-1 medicines may experience potentially blinding eye conditions as soon as the day after starting the drugs, and eye doctors are now asking ...

Although reports of vision problems with weight loss drugs are still rare, researchers say there is cause for concern because ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.